ONCT Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 11.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Oncternal Therapeutics Share Price & Price History
Current Price: $0.53
Price Change: +0.30 (1.20%)
As of 02/23/2026 01:00 AM ET
Oncternal Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/8/2024 | Robert James Wills | Director | Buy | 3,086 | $8.96 | $27,650.56 | 10,000 | |
| 3/28/2024 | Robert James Wills | Director | Buy | 6,914 | $8.48 | $58,630.72 | 6,914 | |
| 2/23/2024 | David F. Hale | Director | Buy | 714 | $9.04 | $6,454.56 | 714 | |
| 6/14/2023 | Gunnar F Kaufmann | Insider | Buy | 150 | $7.20 | $1,080.00 | 4,736 | |
| 6/12/2023 | Gunnar F Kaufmann | Insider | Buy | 1,250 | $7.00 | $8,750.00 | 4,586 | |
| 4/14/2023 | Salim Yazji | Insider | Buy | 250 | $6.00 | $1,500.00 | 8,233 | |
| 4/13/2023 | James B. Breitmeyer | CEO | Buy | 5,000 | $5.80 | $29,000.00 | 7,327 | |
| 4/13/2023 | Richard G Vincent | CFO | Buy | 1,500 | $6.00 | $9,000.00 | 7,842 | |
| 4/12/2023 | Chase C Leavitt | General Counsel | Buy | 750 | $5.80 | $4,350.00 | 4,845 | |
| 4/12/2023 | Salim Yazji | Insider | Buy | 500 | $5.60 | $2,800.00 | 7,483 | |
Oncternal Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 7/19/2024 | Pasadena Private Wealth LLC | 25,000 | $0.19M | 0.0% | N/A | 0.845% |  |
| 5/10/2024 | Richmond Brothers Inc. | 24,696 | $0.22M | 0.4% | -95.0% | 0.834% |  |
| 5/7/2024 | Quantum Private Wealth LLC | 27,806 | $0.25M | 0.1% | N/A | 0.939% |  |
| 1/11/2024 | Pasadena Private Wealth LLC | 500,000 | $0.27M | 0.1% | +79.4% | 16.961% |  |
| 11/3/2023 | Richmond Brothers Inc. | 494,042 | $0.15M | 0.3% | +69.8% | 0.838% |  |
| 10/11/2023 | Pasadena Private Wealth LLC | 278,750 | $84K | 0.0% | N/A | 0.473% |  |
| 8/11/2023 | Richmond Brothers Inc. | 291,032 | $100K | 0.2% | +658.6% | 0.496% |  |
| 8/7/2023 | Acadian Asset Management LLC | 107,967 | $36K | 0.0% | -34.8% | 0.184% |  |
| 5/10/2023 | Richmond Brothers Inc. | 38,362 | $30K | 0.1% | N/A | 0.065% |  |
| 1/23/2023 | Waypoint Capital Advisors LLC | 38,269 | $38K | 0.0% | N/A | 0.068% |  |
| 11/14/2022 | Ergoteles LLC | 100,600 | $90K | 0.0% | -52.8% | 0.179% |  |
| 8/17/2022 | Quantum Private Wealth LLC | 455,656 | $0.51M | 0.3% | +2.4% | 0.856% |  |
| 8/8/2022 | Resources Investment Advisors LLC. | 40,448 | $45K | 0.0% | +33.7% | 0.082% |  |
| 8/5/2022 | Regents of The University of California | 53,554 | $59K | 0.0% | N/A | 0.108% |  |
| 7/27/2022 | Bailard Inc. | 84,200 | $93K | 0.0% | N/A | 0.170% |  |
| 5/12/2022 | Beta Wealth Group Inc. | 32,000 | $44K | 0.0% | N/A | 0.065% |  |
| 5/11/2022 | ACT Capital Management LLC | 225,000 | $0.31M | 0.3% | -37.5% | 0.455% |  |
| 5/11/2022 | GSA Capital Partners LLP | 71,247 | $99K | 0.0% | +519.5% | 0.144% |  |
| 4/26/2022 | Ieq Capital LLC | 144,434 | $0.20M | 0.0% | +100.0% | 0.292% |  |
| 4/19/2022 | Waypoint Capital Advisors LLC | 44,375 | $52K | 0.0% | N/A | 0.090% |  |
| 2/23/2022 | Resources Investment Advisors LLC. | 21,480 | $49K | 0.0% | +52.0% | 0.043% |  |
| 2/14/2022 | IPG Investment Advisors LLC | 23,691 | $54K | 0.0% | -23.0% | 0.048% |  |
| 2/14/2022 | GSA Capital Partners LLP | 11,500 | $26K | 0.0% | N/A | 0.023% |  |
| 2/9/2022 | Principal Financial Group Inc. | 48,218 | $0.11M | 0.0% | -43.0% | 0.098% |  |
| 2/8/2022 | Northern Trust Corp | 396,576 | $0.90M | 0.0% | -30.3% | 0.802% |  |
| 2/7/2022 | SG Americas Securities LLC | 11,890 | $27K | 0.0% | -55.3% | 0.024% |  |
| 2/3/2022 | Advisor Group Holdings Inc. | 21,831 | $50K | 0.0% | -22.3% | 0.044% |  |
| 2/3/2022 | Total Clarity Wealth Management Inc. | 20,056 | $46K | 0.0% | -24.1% | 0.041% |  |
| 1/28/2022 | Allspring Global Investments Holdings LLC | 141,216 | $0.32M | 0.0% | N/A | 0.286% |  |
| 1/19/2022 | Traverso Chambers Private Wealth Management LLC | 12,000 | $27K | 0.0% | N/A | 0.024% |  |
| 1/7/2022 | Vigilare Wealth Management | 49,325 | $0.11M | 0.1% | -22.3% | 0.100% |  |
| 11/16/2021 | Two Sigma Advisers LP | 124,600 | $0.52M | 0.0% | +112.3% | 0.252% |  |
| 11/16/2021 | Two Sigma Investments LP | 452,471 | $1.89M | 0.0% | -18.1% | 0.915% |  |
| 11/16/2021 | United Capital Financial Advisers LLC | 113,410 | $0.47M | 0.0% | +2.5% | 0.229% |  |
| 11/12/2021 | Renaissance Technologies LLC | 142,805 | $0.60M | 0.0% | +173.6% | 0.289% |  |
| 11/12/2021 | Geode Capital Management LLC | 762,449 | $3.18M | 0.0% | +3.1% | 1.543% |  |
| 11/10/2021 | Goldman Sachs Group Inc. | 103,978 | $0.43M | 0.0% | +371.4% | 0.211% |  |
Data available starting January 2016
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.
Read More on Oncternal Therapeutics
Volume
N/A
Average Volume
99,758 shs
Market Capitalization
$1.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.18
Who are the company insiders with the largest holdings of Oncternal Therapeutics?